293 related articles for article (PubMed ID: 35677048)
21. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
Front Immunol; 2022; 13():869297. PubMed ID: 35936012
[TBL] [Abstract][Full Text] [Related]
23. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma.
Zhou P; Liu Z; Hu H; Lu Y; Xiao J; Wang Y; Xun Y; Xia Q; Liu C; Hu J; Wang S
Front Immunol; 2022; 13():901671. PubMed ID: 35720278
[TBL] [Abstract][Full Text] [Related]
25. Integrated single-cell and bulk characterization of branched chain amino acid metabolism-related key gene BCAT1 and association with prognosis and immunogenicity of clear cell renal cell carcinoma.
Zheng J; Liu Y; Wang J; Shi J; Li L; Jiang X; Tao L
Aging (Albany NY); 2024 Feb; 16(3):2715-2735. PubMed ID: 38309289
[TBL] [Abstract][Full Text] [Related]
26. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
27. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
[TBL] [Abstract][Full Text] [Related]
28. Predicting prognosis, immunotherapy and distinguishing cold and hot tumors in clear cell renal cell carcinoma based on anoikis-related lncRNAs.
Hao C; Li R; Lu Z; He K; Shen J; Wang T; Qiu T
Front Immunol; 2023; 14():1145450. PubMed ID: 37359524
[TBL] [Abstract][Full Text] [Related]
29. CHEK2 is a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma.
Wu Q; Fang C; Wang X; Huang S; Weng G
Sci Rep; 2023 Dec; 13(1):21928. PubMed ID: 38081888
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Evaluation of the m
Yu M; Liu X; Xu H; Shen S; Wang F; Chen D; Li G; Wang Z; Zuo Z; Zhao A
Front Immunol; 2022; 13():818120. PubMed ID: 35784363
[TBL] [Abstract][Full Text] [Related]
31. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Davidson G; Helleux A; Vano YA; Lindner V; Fattori A; Cerciat M; Elaidi RT; Verkarre V; Sun CM; Chevreau C; Bennamoun M; Lang H; Tricard T; Fridman WH; Sautes-Fridman C; Su X; Plassard D; Keime C; Thibault-Carpentier C; Barthelemy P; Oudard SM; Davidson I; Malouf GG
Cancer Res; 2023 Sep; 83(17):2952-2969. PubMed ID: 37335139
[TBL] [Abstract][Full Text] [Related]
33. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
34. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
Pan H; Lu W; Zhang M; Liu C
Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
[TBL] [Abstract][Full Text] [Related]
35. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
Front Immunol; 2022; 13():935595. PubMed ID: 35935986
[TBL] [Abstract][Full Text] [Related]
36. The vasculogenic mimicry related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
Gu Y; Huang Q; Wang Y; Wang H; Xiang Z; Xu Y; Wang X; Liu W; Wang A
BMC Cancer; 2024 Apr; 24(1):420. PubMed ID: 38580922
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
38. ARHGAP11A Is a Novel Prognostic and Predictive Biomarker Correlated with Immunosuppressive Microenvironment in Clear Cell Renal Cell Carcinoma.
Yang H; Zhang H; Zhang L; Tusuphan P; Zheng J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175461
[TBL] [Abstract][Full Text] [Related]
39. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract][Full Text] [Related]
40. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
